Changes in Cancer Mortality among HIV‐Infected Patients: The Mortalité 2005 Survey

Bonnet, Fabrice; Burty, C.; Lewden, Charlotte; Costagliola, Dominique; May, Thierry; Bouteloup, Vincent; Rosenthal, Éric; Jougla, Éric; Cacoub, Patrice; Salmon, Dominique; Chêne, Geneviève; Morlat, Philippe

doi:10.1086/596766

Cited by 148 publications

(102 citation statements)

References 19 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…In the HAART era, the incidence of AIDS-defining NHL subtypes decreased in HIV-infected patients (8)(9)(10), and changes in the HIV-associated relative risks partly contributed to the decrease (10), whereas the incidence of Hodgkin lymphoma remained stable and even increased in some HIV/ AIDS cohorts (10)(11)(12). As a result, lymphoma is currently one of the most common cancers and a leading cause of cancer death among people with HIV/AIDS (7,13,14). Among patients with lymphoma, HIV/AIDS status has been strongly associated with poor survival (15,16); however, it remains unclear to what extent this association has changed in the HAART era.…”

Section: Introductionmentioning

confidence: 99%

HIV Infection and Survival of Lymphoma Patients in the Era of Highly Active Antiretroviral Therapy

Han

Jemal

Hulland

et al. 2017

Cancer Epidemiology, Biomarkers &Amp; Prevention

View full text Add to dashboard Cite

show abstract

Section: Introductionmentioning

confidence: 99%

HIV Infection and Survival of Lymphoma Patients in the Era of Highly Active Antiretroviral Therapy

Han

Jemal

Hulland

et al. 2017

Cancer Epidemiology, Biomarkers &Amp; Prevention

View full text Add to dashboard Cite

show abstract

“…1,2 However, despite the reduction in overall mortality and in the proportion of deaths due to opportunistic infections (OI), there has been a concomitant and significant increase in cancer-related mortality. 3,4 Currently, cancer represents the most common cause of death in HIV infected patients. 3,4 Short or mid-term survival (5 years) among HIVinfected patients with AIDS-defining malignancies (ADM) or non-AIDS-defining malignancies (NADM) has been extensively investigated.…”

mentioning

confidence: 99%

“…3,4 Currently, cancer represents the most common cause of death in HIV infected patients. 3,4 Short or mid-term survival (5 years) among HIVinfected patients with AIDS-defining malignancies (ADM) or non-AIDS-defining malignancies (NADM) has been extensively investigated. In the pre-HAART era, the prognosis of patients with HIV-infection and cancer was significantly poorer than that of uninfected subjects with cancer [5][6][7][8] : the overall 2-year survival of patients with non-Hodgkin's lymphoma (NHL) was only 15% 8 against a survival probability greater than 60% in the general population, 9,10 and the 2-year survival of Hodgkin's disease (HD) did not reach 35% 8 compared to a proportion greater than 85% in the general population.…”

mentioning

confidence: 99%

Ten‐year survival among HIV‐1‐infected subjects with AIDS or non‐AIDS‐defining malignancies

Spagnuolo

Galli

Salpietro

et al. 2011

Intl Journal of Cancer

View full text Add to dashboard Cite

Few data are available regarding the 10‐year survival among subjects with HIV and cancer. The aim of this study was to evaluate the 10‐year survival of HIV‐infected subjects with AIDS‐defining malignancies (ADM) or non‐AIDS‐defining malignancies (NADM). This was a single center, retrospective, observational study of subjects with HIV infection and a subsequent cancer diagnosis; the data were collected from January 1991 to April 2010. Malignancies were divided into ADM or NADM on the basis of the Centre of Diseases Control‐1993 classification. Survival curves were estimated using Kaplan–Meyer method and compared by the log‐rank test. Six hundred and fifteen (9.5%) of the 6,495 subjects recorded in the San Raffaele Infectious Diseases Database developed a malignancy: 431 (70%) an ADM and 184 (30%) a NADM. In the case of ADM, survival was more favorable when cancer was diagnosed during post‐highly active antiretroviral therapy (HAART) era (10‐year survival: 43.2% ± 4.4%) than when diagnosed during the pre‐HAART era (10‐year survival: 16.4% ± 2.7%; log‐rank test: p < 0.001). The same was true in the case of NADM (10‐year survival: 44.7% ± 5.5% vs. 33.3 ± 9.6%; log‐rank test: p = 0.03). An evaluation of survival probability by cancer type showed higher survival rates during the post‐HAART era in the case of non‐Hodgkin lymphoma (10‐year survival: 42.1% ± 5.3% vs. 11.4% ± 3.3%; log‐rank test: p = <0.001), Kaposi's sarcoma (10‐year survival: 44.0% ± 8.4% vs. 23.5% ± 3.9%; log‐rank test: p < 0.001) and Hodgkin's disease (10‐year survival: 49.5% ± 14.5% vs. 40.0% ± 12.7%; log‐rank test: p = 0.005). Despite the better cancer prognosis during the post‐HAART era, the 10‐year survival of HIV‐infected subjects with an ADM or NADM is poor.

show abstract

“…21 As mais frequentes são o linfoma de Hodgkin, neoplasia do pulmão, e os carcinomas relacionados com vírus oncogénicos como o carcinoma hepatocelular e neoplasia do canal anal. 1,3,4,9,10 Outras cujo risco parece especificamente aumentado nos doentes com infecção VIH são as neoplasias da cabeça e pescoço, colorectal, próstata, pénis e rim.…”

Section: Discussionunclassified

“…16,18,19 Por último, a utilização de terapêutica anti--retroviral, particularmente dos inibidores não nucleósidos da transcriptase reversa (INNTR), tem sido apontada como potencial factor carcinogénico adicional. 9,20 Apesar de as neoplasias constituírem, actualmente, uma importante causa de mortalidade nos doentes infectados por VIH, 21 na maioria dos casos não há recomendações específicas para o rastreio e tratamento precoces. 19 No caso da European AIDS Clinical Society, estão recomendados alguns rastreios nomeadamente para as neoplasias do canal anal, mama, colo do útero, colo-rectal, fígado e próstata.…”

Section: Introductionunclassified

Infecção VIH e Neoplasias Não Definidoras de SIDA: Experiência de um Centro

Fevereiro

2014

Acta Med Port

View full text Add to dashboard Cite

Introduction: Human Immunodeficiency Virus infected patients have an increased risk for developing different types of cancer. After the introduction of highly active antiretroviral therapy (HAART), and consequent increased survival, a shift has been seen in the spectrum and evolution of HIV infection related diseases, particularly oncological ones, with a tendency to increase non-AIDS-defining malignancies (NADM) as opposed to AIDS defining malignancies. Material and Methods: Characterization of the Human Immunodeficiency Virus infected patients with a non-AIDS defining malignancy diagnosis, followed over 16 years at an outpatient clinic in Lisbon through the review of medical records and retrospective evaluation of demographic, epidemiological, clinical and laboratorial parameters, treatment and mortality. Results: Of the 1042 patients evaluated, there were 34 Non- AIDS defining malignancy cases identified, mostly in men (78%), with a median age of 55 years. The most common cancers were: lung (20.6%), bladder (17.6%), prostate (8.8%), and anal carcinoma (5.9%). The mean time between Human Immunodeficiency Virus infection and non-AIDS-defining malignancy diagnosis was 6.8 ± 4 years. At the time of non-AIDS- defining malignancy diagnosis the majority of patients (78.8%) was receiving HAART for a mean period of 5.7 ± 3 years, most of whom were immune and virologically controlled (64%). There were 45.5% deaths, mainly in patients with lung cancer (20%). Conclusion: Given the risk of developing a non-AIDS-defining malignancy in Human Immunodeficiency Virus-infected patients, it is essential to continue to invest in prevention strategies, promote smoking cessation as well as vaccination programs, as well as applying screening protocols adjusted to this population.

show abstract

Changes in Cancer Mortality among HIV‐Infected Patients: The Mortalité 2005 Survey

Cited by 148 publications

References 19 publications

HIV Infection and Survival of Lymphoma Patients in the Era of Highly Active Antiretroviral Therapy

HIV Infection and Survival of Lymphoma Patients in the Era of Highly Active Antiretroviral Therapy

Ten‐year survival among HIV‐1‐infected subjects with AIDS or non‐AIDS‐defining malignancies

Infecção VIH e Neoplasias Não Definidoras de SIDA: Experiência de um Centro

Contact Info

Product

Resources

About